InflaRx: Strategic Buy Rating Amidst Regulatory Milestones and Promising Pipeline
Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...
Pharmabiz3 天
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced ...
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...
来自MSN3 天
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...
Pharmaceutical Technology3 天
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval
H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...
InflaRx announces EC grants marketing authorization to Gohibic for ARDS
InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress
InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...
Too Old to Operate6 天
Cardiac and Inflammatory Biomarkers for Extubation Failure Risk
The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...